In one case of overdose the patient inadvertently received 8.6 mg of eribulin mesylate (approximately 4 times the planned dose) and subsequently developed a hypersensitivity reaction (Grade 3) on Day 3 and neutropenia (Grade 3) on Day 7.
Both adverse reactions resolved with supportive care.
There is no known antidote for eribulin mesilate overdose. In the event of an overdose, the patient should be closely monitored. Management of overdose should include supportive medical interventions to treat the presenting clinical manifestations.
